Recent advances in the treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Issue 6 (28th December 2022)

• Record Type: Journal Article
• Authors: Jesudas, Rohith; Nichols, Kim E.
• Is Part Of: Current opinion in allergy and clinical immunology. Volume 22:Issue 6(2022)
• Page Start: 364
• Page End: 370
• Publication Date: 2022-12-28
• Subjects: cytokines -- hemophagocytic lymphohistiocytosis -- hyperinflammation -- interferon gamma -- janus kinase -- macrophage activation syndrome; Allergy -- Periodicals; Clinical immunology -- Periodicals; Hypersensitivity; Immunity; Immune System Diseases; Allergy and Immunology; 616.079
• DOI: 10.1097/ACI.0000000000000865
• Languages: English
• ISSNs: 1528-4050

Abstract

Abstract : Purpose of review: The approach to treating patients with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) has shifted in recent years with the aim to limit exposure to genotoxic agents, such as etoposide, yet dampen hyperinflammation by targeting the activity of specific HLH/MAS-associated cytokines. In this review, we discuss recent efforts to reduce the dose of etoposide and/or incorporate cytokine-targeted therapies for the treatment of HLH/MAS. Recent findings: There is emerging evidence that reduced-dose etoposide and/or cytokine-targeted therapies, including agents that neutralize or inhibit signaling induced by interferon gamma, interleukin (IL)-1, IL-18, and IL-6, can effectively ameliorate the clinical and laboratory manifestations of HLH/MAS and improve overall outcomes. Summary: The application of novel regimens containing lower doses of etoposide and/or cytokine-directed agents to treat HLH/MAS holds potential to dampen inflammation while minimizing therapy-associated toxicities. Nevertheless, further research is needed to better understand, which patients represent the most appropriate candidates to receive cytokine-targeted therapies, elucidate the optimal timing and dose of these therapies, and decipher whether they should be administered alone or in combination with conventional HLH-directed therapies, such as dexamethasone and standard-dose or reduced-dose etoposide.